Reviewing ReWalk Robotics (LFWD) & Its Competitors

ReWalk Robotics (NASDAQ:LFWD) is one of 47 public companies in the “Surgical appliances & supplies” industry, but how does it compare to its rivals? We will compare ReWalk Robotics to related businesses based on the strength of its risk, dividends, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Valuation and Earnings

This table compares ReWalk Robotics and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ReWalk Robotics	$13.85 million	-$22.13 million	-1.81
ReWalk Robotics Competitors	$1.32 billion	$152.26 million	20.25

ReWalk Robotics’ rivals have higher revenue and earnings than ReWalk Robotics. ReWalk Robotics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

ReWalk Robotics has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Comparatively, ReWalk Robotics’ rivals have a beta of 0.90, suggesting that their average stock price is 10% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for ReWalk Robotics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReWalk Robotics	0	0	1	0	3.00
ReWalk Robotics Competitors	322	997	2111	86	2.56

ReWalk Robotics currently has a consensus target price of $21.00, suggesting a potential upside of 305.41%. As a group, “Surgical appliances & supplies” companies have a potential upside of 4.57%. Given ReWalk Robotics’ stronger consensus rating and higher possible upside, equities analysts clearly believe ReWalk Robotics is more favorable than its rivals.

Insider and Institutional Ownership

26.8% of ReWalk Robotics shares are owned by institutional investors. Comparatively, 44.7% of shares of all “Surgical appliances & supplies” companies are owned by institutional investors. 2.1% of ReWalk Robotics shares are owned by company insiders. Comparatively, 9.5% of shares of all “Surgical appliances & supplies” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares ReWalk Robotics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReWalk Robotics	-159.76%	-28.19%	-23.29%
ReWalk Robotics Competitors	-73.10%	-71.07%	-15.93%

Summary

ReWalk Robotics rivals beat ReWalk Robotics on 8 of the 13 factors compared.

ReWalk Robotics Company Profile

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.